Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II, open-label, not comparative, multicenter study of multiple doses of NEPA (Netupitant+Palonosetron) in preventing chemotherapy induced nausea and vomiting (CINV) in patient with Non Hodgkin's Lymphoma receiving salvage chemotherapy followed by high dose chemotherapy and autologous hematopoietic stem cells support

Next Previous
X
Search
Trial Profile

Phase II, open-label, not comparative, multicenter study of multiple doses of NEPA (Netupitant+Palonosetron) in preventing chemotherapy induced nausea and vomiting (CINV) in patient with Non Hodgkin's Lymphoma receiving salvage chemotherapy followed by high dose chemotherapy and autologous hematopoietic stem cells support

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Jan 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Netupitant/palonosetron (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use

    • Most Recent Events

    • 01 Feb 2022 Results published in the Supportive Care in Cancer
    • 11 Oct 2021 New source identified and integrated (European Clinical Trials Database: EudraCT2015-003318-26).
    • 04 May 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top